[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sleep-apnea-syndrome-obstructive\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sleep-apnea-syndrome-obstructive":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,73,100,126,147,174,199],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100633716","treatment-failure-of-continuous-positive-airway-pressure-cpap-in-patients-with-obstructive-sleep-apnea-syndrome-osa-a-trial-comparing-polysomnography-and-the-sunrise-device-to-drive-treatment-adjustment-decisions-100633716",false,"NCT07530302","Treatment Failure of Continuous Positive Airway Pressure (CPAP) in Patients With Obstructive Sleep Apnea Syndrome (OSA): A Trial Comparing Polysomnography and the Sunrise Device to Drive Treatment-Adjustment Decisions.","Treatment Failure of Continuous Positive Airway Pressure (CPAP) in Patients With Obstructive Sleep Apnea Syndrome (OSA): A Randomized Controlled Trial Comparing Polysomnography and the Sunrise Device to Drive Treatment-Adjustment Decisions.","SUNCPAP","Inclusion Criteria:\n\n* Adults aged 18 to 85 years\n* Patients treated with Resmed CPAP\n* Residual apnea-hypopnea index under CPAP (rAHI(CPAP) \\> 10 events\u002Fhour)\n* Access to a smartphone and home internet connection, and ability to use a mobile application\n* Signed informed consent\n* Affiliated with, or beneficiary of, a national health insurance program\n\nExclusion Criteria:\n\n* Severe chronic obstructive or restrictive pulmonary disease, with or without supplemental oxygen\n* Unstable cardiovascular disease or severe heart failure requiring hospitalization within the past 3 months, or meeting New York Heart Association (NYHA) class III or IV criteria\n* Conditions affecting mandibular condyle rotation or temporomandibular joint function\n* Refusal to shave excessive facial hair when required for proper placement of the Sunrise device\n* Participation in another interventional clinical study or currently within an exclusion period of another study\n* Individuals who, in the investigator's judgment, are unlikely to comply with study procedures or requirements\n* Individuals who cannot be contacted in case of emergency\n* Persons protected under French Public Health Code articles L1121-5, L1121-6, and L1121-8 (including pregnant or breastfeeding women, persons deprived of liberty, individuals under psychiatric care under articles L.3212-1 or L.3213-1, individuals admitted to healthcare or social institutions for reasons other than research, and persons under legal protection or unable to provide informed consent)\n* Staff members with a hierarchical relationship to the principal investigator","ALL","18 Years","85 Years",{"count":21,"type":22},105,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to determine whether treatment-adjustment decisions based on one night of home monitoring with the Sunrise device are comparable to decisions based on one night of in-laboratory polysomnography (PSG) in adults with obstructive sleep apnea (OSA) who remain insufficiently controlled with continuous positive airway pressure (CPAP) therapy.\n\nThe main questions it aims to answer are:\n\n* Do Sunrise-based assessments lead to similar therapeutic decisions as PSG-based assessments?\n* Are residual apnea-hypopnea indices measured by Sunrise comparable to those measured by PSG?\n\nParticipants will complete both assessment sequences in a randomized cross-over design. They will:\n\n* Use the Sunrise device for several nights with and without CPAP.\n* Undergo one night of PSG with and without CPAP.\n* Have their CPAP therapy reviewed based on the results of each assessment method.",[28],"Sleep Apnea Syndrome, Obstructive",[30,31,32,33],"Obstructive sleep apnea","Randomized","Cross-over","CPAP","RECRUITING","2026-06-15",{"date":37,"type":38},"2026-06-17","ACTUAL",{"date":40,"type":38},"2026-06-10",{"date":42,"type":22},"2029-09",{"name":44,"class":45},"University Hospital, Grenoble","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100599676","sleep-apnea-triggers-of-atrial-fibrillation-n-of-1-randomized-control-trial-sparta-100599676","NCT07087587","Sleep Apnea Triggers of Atrial Fibrillation: N-of-1 Randomized Control Trial (SPARTA):","SPARTA","Inclusion Criteria:\n\n1. Informed consent\n2. Age 18-85 years\n3. High burden paroxysmal AF (≥1%)\n4. Moderate-severe OSA (AHI ≥ 15)\n5. Implanted device with atrial diagnostics\n6. Enrolled in remote monitoring\n\nExclusion Criteria:\n\n1. AF ablation \\\u003C6 months\n2. Valvular abnormalities\n3. Excessive daytime sleepiness in safety-critical jobs\n4. Plans for ablation during study\n5. Non-CPAP OSA treatment\n6. Recent device implantation (\\\u003C6 months)\n7. Central sleep apnea",{"count":55,"type":22},20,[25],"A pilot N-of-1 randomized controlled trial evaluating the effectiveness of a personalized CPAP intervention in reducing atrial fibrillation (AF) burden and improving AF-related quality of life in patients with moderate to severe obstructive sleep apnea (OSA).",[59,28,33],"Afib",[61,33,62],"OSA","AFIB","2026-04-09",{"date":65,"type":38},"2026-04-13",{"date":67,"type":38},"2025-08-25",{"date":69,"type":22},"2026-12-31",{"name":71,"class":45},"The Cleveland Clinic",2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":46},"100632304","bruxism-induced-by-obstructive-sleep-apnoea-100632304","NCT07511946","Bruxism Induced by Obstructive Sleep Apnoea.","Evaluation of the Relationship Between Upper Airway Volume and the Risk of Bruxism Induced by Obstructive Sleep Apnoea.","Inclusion Criteria:\n\n* age equal to\u002Fgreater than 18 years\n* moderate or high risk of sleep apnea according to the STOP-Bang questionnaire\n* presence of bruxism symptoms in the oral cavity according to the current international consensus on bruxism\n* positive history of bruxism during sleep\n\nExclusion Criteria:\n\n* refusal to participate in the study\n* pregnancy\n* breastfeeding\n* presence of severe mental illness\n* alcohol and\u002For drug addiction\n* taking medications that affect the neuromuscular and\u002For respiratory systems\n* severe systemic diseases such as cancer\n* severe neurological and autoimmune diseases\n* multiple missing teeth\n* edentulism in the upper and\u002For lower jaw",true,{"count":82,"type":22},80,"OBSERVATIONAL","The relationship between obstructive sleep apnea (OSA), sleep bruxism, and temporomandibular disorders is becoming clearer, but data on how upper airway volume affects bruxism due to OSA is limited. Recent studies have shown that Cone-Beam Computed Tomography (CBCT) accurately images the upper airway, enabling analysis of its volume and its potential impact on bruxism. CBCT uses low radiation doses, significantly lower than harmful levels, making it a safe method for such assessments. Understanding these relationships can inform clinical practices for managing sleep bruxism, which affects 21% of the global population. The study aims to explore how upper airway volume influences the intensity of sleep bruxism related to OSA.",[28,86,87],"Bruxism, Sleep-Related","Upper Respiratory Tract Illness",[89,86],"Sleep Apnea","NOT_YET_RECRUITING","2026-03-30",{"date":93,"type":38},"2026-04-06",{"date":95,"type":22},"2026-09",{"date":97,"type":22},"2026-11",{"name":99,"class":45},"Wroclaw Medical University",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":4},"100623680","phase-2-botulinum-toxin-in-the-palatopharyngeal-muscle-for-the-treatment-of-obstructive-sleep-apnea-100623680","NCT07399782","Botulinum Toxin in the Palatopharyngeal Muscle for the Treatment of Obstructive Sleep Apnea","EVALUATION OF BOTULINUM TOXIN IN THE PALATOPHARYNGEAL MUSCLE FOR THE TREATMENT OF OBSTRUCTIVE SLEEP APNEA","ARAP1","Inclusion Criteria:\n\n* Diagnosis of moderate to severe OSA, confirmed by home or laboratory polysomnography.\n* Age between 18 and 50 years.\n* BMI in the range of 18.5-30.\n* Neck circumference ≤ 44 cm (men) and ≤ 42 cm (women).\n* Absence of signs of upper obstruction\n\nExclusion Criteria:\n\n* Skeletal or craniofacial disorders:\n* Tonsillar hypertrophy 3-4\n* Obesity (BMI \\> 30 kg\u002Fm²)\n* Elderly (age \\> 50 years)\n* Neuromuscular diseases (e.g., dystrophies, myasthenia gravis)\n* Chronic use of medications that alter muscle tone.\n* Excessive alcohol consumption (\\> 14 drinks\u002Fweek)\n* Chronic obstructive pulmonary disease (COPD)\n* Congestive heart failure (NYHA III-IV) or decompensated heart disease.\n* Concomitant sleep disorders: narcolepsy, restless legs syndrome, sleep behavior disorder (REM).\n* Predominant central or mixed sleep apnea on polysomnography (≥ 50% central events).\n* Previous airway surgery (uvulopalatopharyngoplasty, recent tonsillectomy).\n* Pregnancy or postpartum (\\\u003C 6 months).\n* Neurological conditions: Previous stroke, Parkinson's disease, dementia.","50 Years",{"count":55,"type":22},[111],"PHASE2","Obstructive Sleep Apnea (OSA) is a sleep-related breathing disorder characterized by recurrent collapse of the upper airway during sleep, in which the palatopharyngeal muscle plays a key role in pathophysiology. Although continuous positive airway pressure (CPAP) remains the standard treatment, adherence is often suboptimal. Botulinum toxin type A (BoNT-A), a peripheral neuromodulator, has been proposed as a potential therapeutic alternative by inducing chemodenervation and muscle volume reduction, thereby potentially increasing upper airway patency. This study aims to evaluate the efficacy and safety of BoNT-A injection into the palatopharyngeal muscle in patients with moderate to severe OSA. This is a prospective, single-arm, interventional clinical trial with pre- and post-intervention assessment. We hypothesize that the intervention will result in a significant reduction in the Apnea-Hypopnea Index (AHI), along with improvements in secondary outcomes such as excessive daytime sleepiness and oxygenation parameters.",[28,114,115,116],"Sleep Apnea Syndrome (OSAS)","Sleep Apnea\u002FHypopnea Syndrome","Sleep Apnea - Obstructive","2026-02-05",{"date":119,"type":38},"2026-02-10",{"date":121,"type":22},"2026-04-05",{"date":123,"type":22},"2026-09-01",{"name":125,"class":45},"Hospital Felicio Rocho",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":80,"sex":17,"minAge":18,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":46},"100620411","a-cohort-study-on-increasing-blood-pressure-benefits-in-sleep-apnea-patients-after-cpap-treatment-100620411","NCT07357272","A Cohort Study on Increasing Blood Pressure Benefits in Sleep Apnea Patients After CPAP Treatment","Inclusion Criteria:\n\n1. Age between 18 and 70 years old;\n2. Diagnosed with obstructive sleep apnea (OSA) through overnight polysomnography (PSG), as follows: (1) AHI ≥ 5 times\u002Fhour and one of the following conditions is met: (1) The patient complains of daytime sleepiness, lack of sleepiness during sleep, fatigue or insomnia; (2) Waking up due to breathlessness or wheezing; (3) The bed partner or other witnesses report that the patient has habitual snoring, breathing interruptions or both during sleep. Or (2) AHI ≥ 15 times\u002Fhour.\n3. Satisfy any of the following blood pressure conditions: (1) Office blood pressure 120-139\u002F80-89 mmHg, with ≤ 2 cardiovascular risk factors; (2) Newly diagnosed blood pressure 140-159\u002F90-99 mmHg and without cardiovascular risk factors; (3) Currently taking stable types and doses of antihypertensive drugs, but the office blood pressure has not reached the normal blood pressure standard (120\u002F80 mmHg) with a low-risk level of cardiovascular risk for patients with hypertension; (4) Any non-cardiovascular risk level high-risk patient who voluntarily requests three-month CPAP treatment and accepts follow-up;\n4. Able to tolerate 24-hour ambulatory blood pressure monitoring and continuous blood pressure monitoring;\n\nExclusion Criteria:\n\n1. Previously diagnosed with OSA and currently undergoing OSA treatment (such as CPAP, orthodontic devices, surgery, etc.);\n2. Secondary hypertension caused by other reasons other than OSA, such as renal artery stenosis, kidney disease, Cushing's syndrome, primary aldosteronism;\n3. Unstable condition (having experienced cardiovascular events or major surgeries in the past 3 months, severe sleepiness (ESS ≥ 16 points), or cognitive impairment that makes it impossible to cooperate, active mental illness or drug\u002Falcohol abuse);\n4. Rheumatic immune diseases and malignant tumors;\n5. Large artery diseases (such as giant cell arteritis, arterial dissection, aneurysm, etc.);\n6. Diseases that cannot accurately measure blood pressure (such as atrial fibrillation, upper limb vascular diseases);\n7. Early-onset familial hypertension;\n8. Any prescription or over-the-counter sleep aid (benzodiazepines, non-benzodiazepines, melatonin receptor agonists, trazodone, sedative antipsychotic\u002Fantidepressants containing sedative components, OTC containing sedative components) within 4 weeks before enrollment;\n9. Allergic or contraindicated to the potential study drugs (trazodone, zopiclone);\n10. Pregnant, lactating, or planning to become pregnant;\n11. Frequent night shift work (≥ 3 nights\u002Fweek) or circadian rhythm disorder (diagnosed by a doctor);\n12. Participating in other interventional clinical trials.","70 Years",{"count":134,"type":22},200,"Research Title \"Quadruple-Blind Randomized Controlled Trial of the Effect of CPAP on Blood Pressure in Patients with Sleep Apnea\" Why are we conducting this study?\n\n* Sleep apnea (OSA) is very common, affecting approximately one in every eight adults. It makes it more difficult to control blood pressure.\n* Continuous Positive Airway Pressure (CPAP) is the preferred treatment, but the effect on blood pressure varies from person to person.\n* We want to know: Which patients experience the greatest reduction in blood pressure with CPAP? Can adding a little sleep aid medication for those who have trouble sleeping or frequently wake up at night improve the effectiveness of CPAP and lead to better blood pressure control? Who will participate?\n* 18-70 years old, diagnosed with obstructive sleep apnea, with snoring, gasping, or daytime sleepiness.\n* High blood pressure or newly diagnosed with mild hypertension, or taking 1-2 blood pressure-lowering medications but not reaching the target.\n* Able to wear the CPAP mask every night and willing to undergo 3-month follow-up.\n* Pregnant women, those already using CPAP, those with a history of heart disease\u002Fstroke in the last 3 months, those working night shifts ≥ 3 nights\u002Fweek, or those participating in other intervention trials are not eligible.\n\nWhat will the study do? First, conduct a full-night sleep monitoring and 24-hour blood pressure monitoring to adjust the most suitable CPAP pressure for you.\n\nWear the CPAP mask for ≥ 4 hours every night, for a total of ≥ 21 days per month, for approximately 3 months.\n\nIf you often wake up at night or have insomnia, you can voluntarily join the \"sleep aid medication\" group: take trazodone (25-150 mg) or zolpidem (3.75-7.5 mg) before bedtime for 4 weeks.\n\nDuring this period, we will use questionnaires, a small wristwatch (actigraphy), and additional sleep monitoring to observe changes in sleep and blood pressure; we will also draw a small amount of blood and collect urine for routine safety checks.\n\nYou can withdraw at any time without any penalty and it will not affect your regular medical treatment.\n\nPossible benefits\n\n* Free comprehensive assessment of sleep and blood pressure, one-on-one guidance from a doctor.\n* May lead to a reduction in blood pressure and improvement in nighttime sleep quality.\n* Help future patients like you receive better treatment. Possible discomfort or risks\n* CPAP: mask pressure marks, dry mouth and nose, feeling of suffocation, bloating; most people's symptoms are relieved after adjusting the humidifier or mask.\n* Sleep aid medication: next-day drowsiness, dry mouth, dizziness, nausea; rare cases may include persistent penile erection in men (immediate medical consultation required); the risk of dependency for zolpidem after continuous use for 4 weeks is very low, but it still requires monitoring by a doctor.\n* Check: wearing a blood pressure cuff and sleep monitoring device may cause slight inconvenience during sleep.\n* If there is any injury related to the study, Anzhen Hospital will provide necessary treatment and compensation in accordance with Chinese laws.\n\nPrivacy and Costs\n\n* Sleep monitoring, dynamic blood pressure, medications, and tests required for the study are all free.\n* Your name and medical record will only be viewed by researchers and the ethics committee. Personal identity will not be disclosed when the article is published. Contact person\n* Research Question: Dr. Xie Jiang 010-64456528 (during working days) \u002F 131-6198-5564 (at other times)\n* Rights and Benefits: Beijing Anzhen Hospital Ethics Committee 010-64456214 Voluntary Decision Whether to participate or not is completely voluntary. You can withdraw at any time without any reason, and it will not affect the medical care you are entitled to.",[137,28],"Hypertension (HTN)","2026-01-12",{"date":140,"type":38},"2026-01-21",{"date":142,"type":38},"2025-09-15",{"date":144,"type":22},"2028-07-01",{"name":146,"class":45},"Beijing Anzhen Hospital",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":80,"sex":17,"minAge":154,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":157,"briefSummary":158,"conditions":159,"keywords":162,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":72},"100616127","pilot-study-of-negative-pressure-neck-therapy-npnt-100616127","NCT07301567","Pilot Study of Negative Pressure Neck Therapy (NPNT)","A Proof-of-concept Pilot Study to Determine the Safety and Effectiveness of the Negative Pressure Neck Therapy (NPNT) in Healthy Participants.","Inclusion Criteria:\n\n* Body mass index ≤42 kg\u002Fm2\n* Able to speak, read, and write English\n\nExclusion Criteria:\n\n* Known sleep disorder such as Obstructive Sleep Apnea (OSA), narcolepsy, restless leg syndrome, idiopathic hypersomnolence or chronic insomnia\n* No previous surgery, injury, or radiation to the neck\n* Excessive hair or beard in the area of the neck, and\u002For unwillingness to shave that area for the duration of this study\n* Inflammatory skin condition, such as acne or eczema in the neck area\n* Known silicone allergy\n* Night shift work because of irregular sleep-wake cycles\n* Excessive alcohol intake, defined as that leading to interference with work, home life, or the ability to optimally perform normal everyday duties and tasks\n* Use of illicit drugs currently or within the past 5 years\n* Serious pulmonary disease\n* Use of home oxygen or oxygen saturation \\\u003C94%\n* Cancer that has been in remission for less than one year\n* Previous surgery for peripheral arterial disease","19 Years",{"count":156,"type":22},10,[25],"Obstructive sleep apnea (OSA) is a serious, chronic sleep-related breathing disease in which the upper airway repeatedly collapses during sleep, leading to intermittent oxygen deprivation. This pilot study will evaluate the Safety and Efficacy of Negative Pressure Neck Therapy (NPNT) in up to 10 healthy participants. Participants will undergo 2 separate home sleep apnea tests (HSAT) approximately 1 week apart and will be randomly assigned to wear the NPNT device at either night 1 or night 2 of HSAT. Participation will include 5 on-site visits and 1 phone call over approximately 1 month.",[160,28,161],"Obstructive Apnea","Sleep Disorder (Disorder)",[163,30,164],"sleep apnea","sleep disordered breathing","2025-12-10",{"date":167,"type":38},"2025-12-24",{"date":169,"type":22},"2026-01",{"date":171,"type":22},"2026-12",{"name":173,"class":45},"University of British Columbia",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":181,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":72},"100434927","actigraphy-wearable-eeg-band-and-smartphone-for-sleep-staging-100434927","NCT04943562","Actigraphy, Wearable EEG Band and Smartphone for Sleep Staging","Evaluation of the Viability of Actigraphy, Wearable EEG Band and Smartphone for Sleep Staging in Comparison With Polysomnography","FIRST STAGE (Healthy volunteers)\n\nInclusion Criteria:\n\n* Age between 20 and 80 years old\n* Living in the city of São Paulo, Brazil\n* No physical or intellectual disability that prevent attending to a in-lab polysomnography or understanding its instructions.\n\nExclusion Criteria:\n\n* Excessive daytime sleepiness (as measured by the Epworth Sleepiness Scale)\n* Poor sleep quality (as measured by the Pittsburgh Sleep Quality Index)\n* Insomnia symptoms at any level (as measured by the Insomnia Severity Index)\n* Symptoms of depression (as measured by the Beck Depression Inventory)\n* High risk to sleep apnea (as measured by the Stop-Bang questionnaire)\n* Presence of sleep-related symptoms (as measured by the UNIFESP (Federal University of São Paulo sleep questionnaire)\n* Self-reported abuse of alcohol, use of abuse drugs or use of medicine that might impact the normal sleep pattern (including hypnotics, benzodiazepines, antidepressants, corticosteroids, etc).\n* Self-reported chronic diseases\n* Diagnosis of any sleep disorders during the polysomnography\n\nSECONDS STAGE (volunteers with sleep disorders or complaints)\n\nInclusion Criteria:\n\n* Age between 20 and 80 years old\n* Living in the city of São Paulo, Brazil\n* No physical or intellectual disability that prevent attending to a in-lab polysomnography or understanding its instructions.\n* At least one sleep disorder or sleep complaint. . Among these, at least 30% of the sample should have moderate to severe insomnia (as measured by the insomnia severity index), 30% should have high risk to sleep apnea (as measured by the STOP-BANG questionnaire) and 70% should have excessive sleepiness scale (as measured by the Epworth sleepiness scale).\n\nExclusion criteria:\n\n* Absence of sleep disorders.","20 Years","80 Years",{"count":184,"type":22},96,"This study aims to evaluate the viability of the combined use of wearable and portable technologies for sleep staging. The results will be compared with polysomnography, in order to achieve clinical and diagnostic validation. Three domains of devices will be used: Movement sensors, wearable EEG band and smartphones\n\nThe project will be composed of two stages:\n\nIn the first stage, the use of the combination of actigraphy and EEG will be used for sleep staging in a sample of 12 healthy volunteers from 20 to 80 years old, both genders and with no sleep disorders for each combination of ACT+EEG. Considering there will two of each (thus four combinations), the final sample will be composed of 48 individuals. Once recruited, evaluated according to the inclusion and exclusion criteria and consented with the terms of this study, the participants will be referred to the sleep lab, in which they will undergo a full night type-1 in lab polysomnography, following the setup recommended by the American Academy of Sleep Medicine. Concomitantly with the polysomnography, the participants will also use the combination of ACT+EEG.\n\nIn the second stage, the most successful combination tested in the first stage will be tested in a clinical sample, composed by 60 participants from both genders, from 20 to 80 years old and with at least one sleep disorder or complaint. Among these, at least 30% of the sample should have moderate to severe insomnia, 30% should have high risk to sleep apnea and 70% should have excessive sleepiness scale. All the procedures, including the polysomnography will be performed identically to the first step.",[187,188,28],"Sleep","Insomnia","2025-11-24",{"date":191,"type":38},"2025-12-02",{"date":193,"type":38},"2021-09-09",{"date":195,"type":22},"2026-12-01",{"name":197,"class":198},"SleepUp Tecnologia em Saúde Ltda","INDUSTRY",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":207,"targetDuration":209,"studyType":83,"phases":4,"briefSummary":210,"conditions":211,"keywords":212,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":72},"100561139","the-snore-trial-analysis-of-alterations-in-sleep-stages-following-anesthesia-and-their-relation-to-the-severity-of-obstructive-sleep-apnea-in-the-first-3-nights-after-surgery-100561139","NCT06586268","The SNORE-trial: Analysis of Alterations in Sleep Stages Following Anesthesia and Their Relation to the Severity of Obstructive Sleep Apnea in the First 3 Nights After Surgery","The SNORE-trial: Postoperative REM-Sleep Disturbance iN Obstructive Sleep-apnea Patients and the Relation With AH-index","SNORE","Inclusion Criteria:\n\n* Patients scheduled for elective surgery at the operating theatres of the AUMC with a diagnosis of OSA with or without treatment with an expected admittance of a minimum of 3 days\n* Patients with continuous positive airway pressure (CPAP) or mandibular advancement device (MAD) are considered patients with treatment for OSA\n* Patients ≥ 18 years\n* Dutch or English speaking\n* Willing and able to sign consent for re-use of care data\n\nExclusion Criteria:\n\n* Patients \\< 18 years\n* Not speaking Dutch or English\n* Patients who do not sign consent for re-use of care data\n* Surgery scheduled in day case or with an expected discharge before the third night after surgery",{"count":208,"type":22},35,"3 Days","The goal of this observational study is to learn about the relationship between sleep alterations following anesthesia and their relationship to a potential increase of obstructive sleep apnea (OSA) severity.\n\nOur main question is: Is there an increased severity of OSA on the third post-operative night compared to the first post-operative night and does this have a relation with REM sleep?\n\nParticipants enrolled in this research are all diagnosed with OSA, with or without treament. All participants will be asked to wear a watchlike device called WATCHPAT to identify sleep paterns and register apneic (no breathing) and hypopneic (insufficient breathing) incidents. We ask our participants to wear this device for 8-10 hours a night when they are a sleep.",[28,114],[213,61,214,215,216,217,218,219,220],"OSAS","obstructive sleep apnea","Post-surgical","post-anesthesia","REM sleep","PACU","AHI","Desaturations","2025-01-28",{"date":223,"type":38},"2025-01-29",{"date":225,"type":38},"2024-10-01",{"date":227,"type":22},"2025-08",{"name":229,"class":45},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"]